Enanta Pharmaceuticals, Inc. (ENTA)
12.31
-0.19
(-1.52%)
USD |
NASDAQ |
Oct 12, 16:00
12.31
0.00 (0.00%)
After-Hours: 17:57
Enanta Pharmaceuticals Cash from Investing (Quarterly) : 14.00M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.00M |
| March 31, 2026 | 11.94M |
| December 31, 2025 | -47.30M |
| September 30, 2025 | 2.296M |
| June 30, 2025 | -26.48M |
| March 31, 2025 | -4.369M |
| December 31, 2024 | 68.90M |
| September 30, 2024 | 19.07M |
| June 30, 2024 | -6.345M |
| March 31, 2024 | 58.62M |
| December 31, 2023 | -13.12M |
| September 30, 2023 | 11.84M |
| June 30, 2023 | -145.75M |
| March 31, 2023 | 46.76M |
| December 31, 2022 | 33.57M |
| September 30, 2022 | 28.23M |
| June 30, 2022 | 16.22M |
| March 31, 2022 | -35.06M |
| December 31, 2021 | 45.50M |
| September 30, 2021 | 72.68M |
| June 30, 2021 | -43.70M |
| March 31, 2021 | 25.46M |
| December 31, 2020 | -17.44M |
| September 30, 2020 | 2.504M |
| June 30, 2020 | 26.78M |
| Date | Value |
|---|---|
| March 31, 2020 | 27.75M |
| December 31, 2019 | -37.20M |
| September 30, 2019 | -52.21M |
| June 30, 2019 | -14.85M |
| March 31, 2019 | 1.322M |
| December 31, 2018 | -20.93M |
| September 30, 2018 | -7.949M |
| June 30, 2018 | -31.46M |
| March 31, 2018 | 6.457M |
| December 31, 2017 | -2.448M |
| September 30, 2017 | -14.90M |
| June 30, 2017 | 7.658M |
| March 31, 2017 | 1.806M |
| December 31, 2016 | 0.865M |
| September 30, 2016 | -6.147M |
| June 30, 2016 | -31.43M |
| March 31, 2016 | -0.457M |
| December 31, 2015 | -5.632M |
| September 30, 2015 | 4.098M |
| June 30, 2015 | 8.174M |
| March 31, 2015 | -107.48M |
| December 31, 2014 | 7.027M |
| September 30, 2014 | 9.213M |
| June 30, 2014 | -27.31M |
| March 31, 2014 | 17.25M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 15.02M |
| Coherus Oncology, Inc. | 29.63M |
| BridgeBio Pharma, Inc. | 17.89M |
| RenovoRx, Inc. | -0.071M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -9.972M |
| Cash from Financing (Quarterly) | -5.542M |
| Free Cash Flow | -36.94M |
| Free Cash Flow Per Share (Quarterly) | -0.343 |
| Free Cash Flow to Equity (Quarterly) | -5.402M |
| Free Cash Flow to Firm (Quarterly) | -5.841M |
| Free Cash Flow Yield | -11.09% |